Details of the Drug

General Information of Drug (ID: DMZAL7W)

• Drug Name: Promazine
• Synonyms: Ampazine; Berophen; Esparin; Liranol; Prazin; Prazine; Promazin; Promazina; Promazinum; Promwill; Propazinum; Protactyl; Romtiazin; Sinophenin; Tomil; Verophen; Combelen [veterinary]; Promazina [Italian]; A 145; RP 3276; WY 1094; Combelen [veterinary] (TN); Neo-Hibernex; Promazina [INN-Spanish]; Promazine (INN); Promazine [INN:BAN]; Promazinum [INN-Latin]; Sparine (TN); Wy-1094; N-(3-Dimethylaminopropyl)phenothiazine; N-Dimethylamino-1-methylethyl thiodiphenylamine; Dimethyl(3-phenothiazin-10-ylpropyl)amine; N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; 10-(3-(Dimethylamino)propyl)phenothiazine; 10-[3-(Dimethylamino)propyl]phenothiazine; 10H-Phenothiazine-10-propanamine, N,N-dimethyl-(9CI); 10H-Phenothiazine-10-propanamine, N,N-dimethyl-, monohydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Acute intermittent hepatic porphyria	5C58.11	Approved	[1]
Allergic rhinitis	CA08.0	Approved	[1]
Angioedema	4A00.15	Approved	[1]
Disruptive behavior disorder	N.A.	Approved	[1]
Nausea	MD90	Approved	[1]
Psychomotor agitation	MB23.M	Approved	[2]
Psychotic disorder	6A20-6A25	Approved	[1]
Urticaria	EB00-EB05	Approved	[1]
Vomiting	MD90	Approved	[1]
Pruritus	EC90	Investigative	[1]

• Therapeutic Class: Antipsychotic Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 284.4
  Logarithm of the Partition Coefficient (xlogp); 4.5
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [4]
  Elimination: 2% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 7.9 hours [4]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 50.2258 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.11% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 8.1 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 333.33 mg/mL [3]
• Chemical Identifiers:
  Formula: C17H20N2S
  IUPAC Name: N,N-dimethyl-3-phenothiazin-10-ylpropan-1-amine
  Canonical SMILES: CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
  InChI: InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
  InChIKey: ZGUGWUXLJSTTMA-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4926
  ChEBI ID: CHEBI:8459
  CAS Number: 58-40-2
  DrugBank ID: DB00420
  TTD ID: D00NAX
  VARIDT ID: DR00887
  INTEDE ID: DR1351
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor M5 (CHRM5)	TTH18TF	ACM5_HUMAN	Binder	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[8]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[7]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Gene/Protein Processing	[9]
Corticoliberin (CRH)	OT2MOC4T	CRF_HUMAN	Gene/Protein Processing	[10]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[11]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Promazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Promazine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[12]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Midostaurin.	Acute myeloid leukaemia [2A60]	[13]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[13]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Arn-509.	Acute myeloid leukaemia [2A60]	[14]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[15]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Promazine and Oliceridine.	Acute pain [MG31]	[16]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Promazine and Scopolamine.	Addictive disorder [6C50-6C5Z]	[17]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Promazine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[18]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Promazine and Memantine.	Alzheimer disease [8A20]	[17]
Galantamine	DMEO794	Moderate	Antagonize the effect of Promazine when combined with Galantamine.	Alzheimer disease [8A20]	[19]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Promazine when combined with Rivastigmine.	Alzheimer disease [8A20]	[19]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Promazine when combined with Donepezil.	Alzheimer disease [8A20]	[19]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Promazine and Metronidazole.	Amoebiasis [1A36]	[20]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Promazine and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[21]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Promazine and Ivabradine.	Angina pectoris [BA40]	[14]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Promazine and Dronedarone.	Angina pectoris [BA40]	[13]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Promazine and Amyl nitrite.	Angina pectoris [BA40]	[21]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Promazine and Nifedipine.	Angina pectoris [BA40]	[21]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Promazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[22]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Promazine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[17]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Cilostazol.	Arterial occlusive disease [BD40]	[13]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Posaconazole.	Aspergillosis [1F20]	[13]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Levalbuterol.	Asthma [CA23]	[23]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Terbutaline.	Asthma [CA23]	[24]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Pirbuterol.	Asthma [CA23]	[23]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Salbutamol.	Asthma [CA23]	[23]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Formoterol.	Asthma [CA23]	[24]
Lisdexamfetamine	DM6W8V5	Moderate	Antagonize the effect of Promazine when combined with Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[25]
Methylphenidate	DM7SJD6	Moderate	Antagonize the effect of Promazine when combined with Methylphenidate.	Attention deficit hyperactivity disorder [6A05]	[25]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[26]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[13]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[13]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Promazine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[13]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Promazine and Linezolid.	Bacterial infection [1A00-1C4Z]	[27]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[26]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Telithromycin.	Bacterial infection [1A00-1C4Z]	[13]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Retigabine.	Behcet disease [4A62]	[28]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Promazine and Cariprazine.	Bipolar disorder [6A60]	[17]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Promazine and Loperamide.	Bowel habit change [ME05]	[29]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Eribulin.	Breast cancer [2C60-2C6Y]	[13]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[13]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Promazine and Toremifene.	Breast cancer [2C60-2C6Y]	[13]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Promazine and Sotalol.	Cardiac arrhythmia [BC9Z]	[13]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Promazine when combined with Acetylcholine.	Cataract [9B10]	[30]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Promazine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[31]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Promazine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[32]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Promazine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[32]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Promazine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[32]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Promazine and Dihydrocodeine.	Chronic pain [MG30]	[16]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Oxaliplatin.	Colorectal cancer [2B91]	[13]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Isoproterenol.	Conduction disorder [BC63]	[23]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Promazine and Olopatadine.	Conjunctiva disorder [9A60]	[33]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Halothane.	Corneal disease [9A76-9A78]	[13]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Propofol.	Corneal disease [9A76-9A78]	[34]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Sevoflurane.	Corneal disease [9A76-9A78]	[13]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Promazine and Alfentanil.	Corneal disease [9A76-9A78]	[35]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Promazine and Remifentanil.	Corneal disease [9A76-9A78]	[35]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Clofazimine.	Crohn disease [DD70]	[36]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Promazine and Mifepristone.	Cushing syndrome [5A70]	[13]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Promazine and Pasireotide.	Cushing syndrome [5A70]	[13]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Sertraline.	Depression [6A70-6A7Z]	[13]
Trimipramine	DM1SC8M	Moderate	Increased plasma concentrations of Promazine and Trimipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[37]
Imipramine	DM2NUH3	Moderate	Increased plasma concentrations of Promazine and Imipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[37]
Fluoxetine	DM3PD2C	Moderate	Decreased metabolism of Promazine caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[38]
Nortriptyline	DM4KDYJ	Moderate	Increased plasma concentrations of Promazine and Nortriptyline due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[37]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Promazine caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[39]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Promazine and Selegiline.	Depression [6A70-6A7Z]	[27]
Duloxetine	DM9BI7M	Moderate	Decreased metabolism of Promazine caused by Duloxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[40]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Promazine and Isocarboxazid.	Depression [6A70-6A7Z]	[27]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Promazine and Escitalopram.	Depression [6A70-6A7Z]	[13]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Promazine and OPC-34712.	Depression [6A70-6A7Z]	[17]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Promazine and Phenelzine.	Depression [6A70-6A7Z]	[27]
Clomipramine	DMINRKW	Moderate	Increased plasma concentrations of Promazine and Clomipramine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[37]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Trazodone.	Depression [6A70-6A7Z]	[41]
Amoxapine	DMKITQE	Moderate	Increased plasma concentrations of Promazine and Amoxapine due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[37]
Doxepin	DMPI98T	Moderate	Increased plasma concentrations of Promazine and Doxepin due to competitive inhibition of the same metabolic pathway.	Depression [6A70-6A7Z]	[42]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Promazine and Maprotiline.	Depression [6A70-6A7Z]	[17]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Promazine and Esketamine.	Depression [6A70-6A7Z]	[20]
Nitroglycerin	DMQ2491	Moderate	Additive hypotensive effects by the combination of Promazine and Nitroglycerin.	Diabetic foot ulcer [BD54]	[21]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Promazine and Hyoscyamine.	Digestive system disease [DE2Z]	[17]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Promazine and Mepenzolate.	Digestive system disease [DE2Z]	[18]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Promazine and Oxybutynine.	Discovery agent [N.A.]	[17]
Tetrabenazine	DMYWQ0O	Major	Additive antidopaminergic effects by the combination of Promazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[43]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Promazine and Meclizine.	Dizziness and giddiness [MB48]	[17]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Promazine and Deutetrabenazine.	Dystonic disorder [8A02]	[44]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Ingrezza.	Dystonic disorder [8A02]	[45]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Promazine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[46]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Promazine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[47]
Guanabenz	DM5QWEL	Moderate	Additive hypotensive effects by the combination of Promazine and Guanabenz.	Essential hypertension [BA00]	[48]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Promazine and Ethacrynic acid.	Essential hypertension [BA00]	[48]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Promazine and Phenoxybenzamine.	Essential hypertension [BA00]	[21]
Nicardipine	DMCDYW7	Moderate	Additive hypotensive effects by the combination of Promazine and Nicardipine.	Essential hypertension [BA00]	[21]
Mecamylamine	DMGQFYB	Moderate	Additive hypotensive effects by the combination of Promazine and Mecamylamine.	Essential hypertension [BA00]	[21]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Promazine and Nadolol.	Essential hypertension [BA00]	[21]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Solifenacin.	Functional bladder disorder [GC50]	[13]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Promazine and Tolterodine.	Functional bladder disorder [GC50]	[17]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Promazine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[49]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Pentamidine.	Fungal infection [1F29-1F2F]	[13]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Promazine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[50]
Amphotericin B	DMTAJQE	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Amphotericin B.	Fungal infection [1F29-1F2F]	[20]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Promazine and Phentolamine.	Gangrene [MC85]	[21]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Promazine and Propantheline.	Gastric ulcer [DA60]	[17]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[13]
Acetazolamide	DM1AF5U	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Acetazolamide.	Glaucoma [9C61]	[20]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Promazine and Brimonidine.	Glaucoma [9C61]	[51]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Promazine when combined with Pilocarpine.	Glaucoma [9C61]	[30]
Spironolactone	DM2AQ5N	Moderate	Additive hypotensive effects by the combination of Promazine and Spironolactone.	Heart failure [BD10-BD1Z]	[21]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Promazine and Prazosin.	Heart failure [BD10-BD1Z]	[21]
Eplerenone	DMF0NQR	Moderate	Additive hypotensive effects by the combination of Promazine and Eplerenone.	Heart failure [BD10-BD1Z]	[21]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Promazine and Carvedilol.	Heart failure [BD10-BD1Z]	[21]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[20]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Furosemide.	Heart failure [BD10-BD1Z]	[20]
Amiloride	DMRTSGP	Moderate	Additive hypotensive effects by the combination of Promazine and Amiloride.	Heart failure [BD10-BD1Z]	[21]
Bumetanide	DMRV7H0	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Bumetanide.	Heart failure [BD10-BD1Z]	[20]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[20]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Promazine and Procarbazine.	Hodgkin lymphoma [2B30]	[27]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Promazine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Promazine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Promazine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[54]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Promazine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[21]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Promazine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[20]
Eprosartan	DM07K2I	Moderate	Additive hypotensive effects by the combination of Promazine and Eprosartan.	Hypertension [BA00-BA04]	[21]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Promazine and Acebutolol.	Hypertension [BA00-BA04]	[21]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Promazine and Moexipril.	Hypertension [BA00-BA04]	[21]
Bisoprolol	DM3UZ95	Moderate	Additive hypotensive effects by the combination of Promazine and Bisoprolol.	Hypertension [BA00-BA04]	[21]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Promazine and Captopril.	Hypertension [BA00-BA04]	[21]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Promazine and Trandolapril.	Hypertension [BA00-BA04]	[21]
Methyldopa	DM5I621	Moderate	Additive hypotensive effects by the combination of Promazine and Methyldopa.	Hypertension [BA00-BA04]	[21]
Clonidine	DM6RZ9Q	Moderate	Additive hypotensive effects by the combination of Promazine and Clonidine.	Hypertension [BA00-BA04]	[21]
Losartan	DM72JXH	Moderate	Additive hypotensive effects by the combination of Promazine and Losartan.	Hypertension [BA00-BA04]	[21]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Promazine and Nebivolol.	Hypertension [BA00-BA04]	[21]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Promazine and Levamlodipine.	Hypertension [BA00-BA04]	[21]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Promazine and Fosinopril.	Hypertension [BA00-BA04]	[21]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Promazine and Doxazosin.	Hypertension [BA00-BA04]	[21]
Verapamil	DMA7PEW	Moderate	Additive hypotensive effects by the combination of Promazine and Verapamil.	Hypertension [BA00-BA04]	[21]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Promazine and TAK-491.	Hypertension [BA00-BA04]	[21]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Promazine and Fenoldopam.	Hypertension [BA00-BA04]	[21]
Indapamide	DMGN1PW	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Indapamide.	Hypertension [BA00-BA04]	[20]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Promazine and Benazepril.	Hypertension [BA00-BA04]	[21]
Labetalol	DMK8U72	Moderate	Additive hypotensive effects by the combination of Promazine and Labetalol.	Hypertension [BA00-BA04]	[21]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Promazine and Diazoxide.	Hypertension [BA00-BA04]	[21]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Promazine and Enalapril.	Hypertension [BA00-BA04]	[21]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Promazine and Perindopril.	Hypertension [BA00-BA04]	[21]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Promazine and Felodipine.	Hypertension [BA00-BA04]	[21]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Promazine and Quinapril.	Hypertension [BA00-BA04]	[21]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Promazine and Telmisartan.	Hypertension [BA00-BA04]	[21]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Promazine and Irbesartan.	Hypertension [BA00-BA04]	[21]
Hydralazine	DMU8JGH	Moderate	Additive hypotensive effects by the combination of Promazine and Hydralazine.	Hypertension [BA00-BA04]	[21]
Lisinopril	DMUOK4C	Moderate	Additive hypotensive effects by the combination of Promazine and Lisinopril.	Hypertension [BA00-BA04]	[21]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[20]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[20]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Promazine and ITI-007.	Insomnia [7A00-7A0Z]	[17]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Promazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[13]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Promazine and Clidinium.	Irritable bowel syndrome [DD91]	[17]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Promazine and Dicyclomine.	Irritable bowel syndrome [DD91]	[17]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Promazine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[19]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Promazine and Crizotinib.	Lung cancer [2C25]	[55]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Promazine and Porfimer Sodium.	Lung cancer [2C25]	[56]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Promazine and Ceritinib.	Lung cancer [2C25]	[13]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Promazine and Osimertinib.	Lung cancer [2C25]	[57]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Promazine and Selpercatinib.	Lung cancer [2C25]	[58]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Promazine and Lumefantrine.	Malaria [1F40-1F45]	[20]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Promazine and Chloroquine.	Malaria [1F40-1F45]	[59]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Promazine and Hydroxychloroquine.	Malaria [1F40-1F45]	[59]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Quinine.	Malaria [1F40-1F45]	[13]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Primaquine.	Malaria [1F40-1F45]	[13]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[14]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Promazine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[60]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Promazine and Vemurafenib.	Melanoma [2C30]	[13]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Promazine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[61]
Propranolol	DM79NTF	Moderate	Additive hypotensive effects by the combination of Promazine and Propranolol.	Migraine [8A80]	[21]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Promazine and Lasmiditan.	Migraine [8A80]	[62]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Promazine and Panobinostat.	Multiple myeloma [2A83]	[63]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Promazine and Thalidomide.	Multiple myeloma [2A83]	[14]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Promazine and Siponimod.	Multiple sclerosis [8A40]	[20]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Promazine and Fingolimod.	Multiple sclerosis [8A40]	[64]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Promazine and Ozanimod.	Multiple sclerosis [8A40]	[14]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Promazine and Methoxsalen.	Mycosis fungoides [2B01]	[20]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Romidepsin.	Mycosis fungoides [2B01]	[28]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Promazine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[13]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Promazine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[65]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[66]
Dextroamphetamine	DMMIHVP	Moderate	Antagonize the effect of Promazine when combined with Dextroamphetamine.	Narcolepsy [7A20]	[25]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Promazine and Droperidol.	Nausea/vomiting [MD90]	[13]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Promazine and Dimenhydrinate.	Nausea/vomiting [MD90]	[17]
Prochlorperazine	DM53SRA	Moderate	Additive anticholinergic effects by the combination of Promazine and Prochlorperazine.	Nausea/vomiting [MD90]	[17]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Promazine and Promethazine.	Nausea/vomiting [MD90]	[17]
Metoclopramide	DMFA5MY	Major	Additive antidopaminergic effects by the combination of Promazine and Metoclopramide.	Nausea/vomiting [MD90]	[67]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Granisetron.	Nausea/vomiting [MD90]	[13]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Ondansetron.	Nausea/vomiting [MD90]	[13]
Bupropion	DM5PCS7	Major	Decreased metabolism of Promazine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[13]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Entrectinib.	Non-small cell lung cancer [2C25]	[14]
Phendimetrazine	DM6TS1N	Moderate	Antagonize the effect of Promazine when combined with Phendimetrazine.	Obesity [5B80-5B81]	[25]
Amfepramone	DM9YSNQ	Moderate	Antagonize the effect of Promazine when combined with Amfepramone.	Obesity [5B80-5B81]	[25]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Promazine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[68]
Benzphetamine	DMIJATC	Moderate	Antagonize the effect of Promazine when combined with Benzphetamine.	Obesity [5B80-5B81]	[25]
Metolazone	DMB39LO	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Metolazone.	Oedema [MG29]	[20]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Polythiazide.	Oedema [MG29]	[20]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Lofexidine.	Opioid use disorder [6C43]	[13]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Promazine and Apraclonidine.	Optic nerve disorder [9C40]	[51]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Rucaparib.	Ovarian cancer [2C73]	[13]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Promazine and Pentazocine.	Pain [MG30-MG3Z]	[35]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Promazine and Dextropropoxyphene.	Pain [MG30-MG3Z]	[69]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Promazine and Butorphanol.	Pain [MG30-MG3Z]	[35]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Promazine and Oxymorphone.	Pain [MG30-MG3Z]	[35]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Promazine and Levorphanol.	Pain [MG30-MG3Z]	[35]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Promazine and Flavoxate.	Pain [MG30-MG3Z]	[17]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Promazine and Nalbuphine.	Pain [MG30-MG3Z]	[35]
Methamphetamine	DMPM4SK	Moderate	Antagonize the effect of Promazine when combined with Methamphetamine.	Pain [MG30-MG3Z]	[70]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Promazine and Buprenorphine.	Pain [MG30-MG3Z]	[71]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Promazine and Hydrocodone.	Pain [MG30-MG3Z]	[35]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Promazine and Meperidine.	Pain [MG30-MG3Z]	[35]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Promazine and Oxycodone.	Pain [MG30-MG3Z]	[35]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Triclabendazole.	Parasitic worm infestation [1F90]	[28]
Pergolide	DM14MAE	Moderate	Antagonize the effect of Promazine when combined with Pergolide.	Parkinsonism [8A00]	[72]
Opicapone	DM1BKA6	Moderate	Antagonize the effect of Promazine when combined with Opicapone.	Parkinsonism [8A00]	[73]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Promazine and Rasagiline.	Parkinsonism [8A00]	[27]
Biperiden	DME78OA	Moderate	Antagonize the effect of Promazine when combined with Biperiden.	Parkinsonism [8A00]	[74]
Entacapone	DMLBVKQ	Moderate	Antagonize the effect of Promazine when combined with Entacapone.	Parkinsonism [8A00]	[72]
Levodopa	DMN3E57	Moderate	Additive hypotensive effects by the combination of Promazine and Levodopa.	Parkinsonism [8A00]	[72]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Pimavanserin.	Parkinsonism [8A00]	[75]
Bromocriptine	DMVE3TK	Moderate	Antagonize the effect of Promazine when combined with Bromocriptine.	Parkinsonism [8A00]	[72]
Apomorphine	DMX38HQ	Moderate	Antagonize the effect of Promazine when combined with Apomorphine.	Parkinsonism [8A00]	[76]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Promazine and Methylscopolamine.	Peptic ulcer [DA61]	[17]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Famotidine.	Peptic ulcer [DA61]	[20]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Promazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[77]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Promazine and Lefamulin.	Pneumonia [CA40]	[12]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[20]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Degarelix.	Prostate cancer [2C82]	[14]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Promazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[78]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Nilutamide.	Prostate cancer [2C82]	[14]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Enzalutamide.	Prostate cancer [2C82]	[14]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Flutamide.	Prostate cancer [2C82]	[14]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Bicalutamide.	Prostate cancer [2C82]	[14]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Promazine and Terazosin.	Prostate hyperplasia [GA90]	[21]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Promazine and Tamsulosin.	Prostate hyperplasia [GA90]	[21]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Promazine and Silodosin.	Prostate hyperplasia [GA90]	[21]
Verteporfin	DMIY6DB	Moderate	Increased risk of photosensitivity reactions by the combination of Promazine and Verteporfin.	Psoriasis [EA90]	[14]
Fluphenazine	DMIT8LX	Moderate	Additive anticholinergic effects by the combination of Promazine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[17]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Promazine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[79]
Neupro	DMHEAB1	Moderate	Antagonize the effect of Promazine when combined with Neupro.	Restless legs syndrome [7A80]	[72]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Promazine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[80]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Promazine and Cyproheptadine.	Rheumatoid arthritis [FA20]	[17]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Quetiapine.	Schizophrenia [6A20]	[13]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Promazine and Mesoridazine.	Schizophrenia [6A20]	[20]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Promazine and Thioridazine.	Schizophrenia [6A20]	[81]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Promazine and Aripiprazole.	Schizophrenia [6A20]	[17]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Promazine and Iloperidone.	Schizophrenia [6A20]	[13]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Paliperidone.	Schizophrenia [6A20]	[13]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Promazine and Haloperidol.	Schizophrenia [6A20]	[13]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Promazine and Molindone.	Schizophrenia [6A20]	[17]
Chlorpromazine	DMBGZI3	Moderate	Additive anticholinergic effects by the combination of Promazine and Chlorpromazine.	Schizophrenia [6A20]	[17]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Promazine and Thiothixene.	Schizophrenia [6A20]	[17]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Promazine and Trifluoperazine.	Schizophrenia [6A20]	[17]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Promazine and Risperidone.	Schizophrenia [6A20]	[17]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Promazine and Amisulpride.	Schizophrenia [6A20]	[82]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Asenapine.	Schizophrenia [6A20]	[13]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Promazine and Pimozide.	Schizophrenia [6A20]	[14]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Promazine and Fentanyl.	Sensation disturbance [MB40]	[35]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[13]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Promazine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[13]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[13]
Cisplatin	DMRHGI9	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Cisplatin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Promazine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[13]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[13]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Pitolisant.	Somnolence [MG42]	[13]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[13]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Promazine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[13]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Lenvatinib.	Thyroid cancer [2D10]	[13]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Promazine and Cabozantinib.	Thyroid cancer [2D10]	[14]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Promazine and Tizanidine.	Tonus and reflex abnormality [MB47]	[83]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Tacrolimus.	Transplant rejection [NE84]	[13]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Promazine and Atropine.	Unspecific substance harmful effect [NE6Z]	[17]
Triprolidine	DM7SWIA	Moderate	Additive anticholinergic effects by the combination of Promazine and Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[17]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Promazine and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[17]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Promazine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[17]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Promazine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[18]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Promazine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[13]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[13]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Promazine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[13]

References

• [1] Promazine FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12.
• [7] Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
• [8] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [9] Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
• [10] Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology. 2006 Apr;31(4):853-65. doi: 10.1038/sj.npp.1300911.
• [11] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [12] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [13] Canadian Pharmacists Association.
• [14] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [15] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [16] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [17] Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
• [18] Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
• [19] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [20] Cerner Multum, Inc. "Australian Product Information.".
• [21] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [22] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [23] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [24] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [25] Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
• [26] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [27] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [28] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
• [29] Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
• [30] Multum Information Services, Inc. Expert Review Panel.
• [31] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [32] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
• [33] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [34] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [35] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [36] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [37] Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
• [38] Avenoso A, Spina E, Campo G, Facciola G, Ferlito M, Zuccaro P, Perucca E, Caputi AP "Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications." Pharmacol Res 35 (1997): 335-9. [PMID: 9264051]
• [39] Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
• [40] Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
• [41] Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
• [42] Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
• [43] Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
• [44] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [45] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [46] Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
• [47] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
• [48] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [49] Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
• [50] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [51] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [52] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [53] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [54] Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
• [55] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [56] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
• [57] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [58] Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
• [59] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [60] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [61] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [62] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [63] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [64] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [65] Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
• [66] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [67] Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
• [68] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
• [69] Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
• [70] Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
• [71] Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
• [72] Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
• [73] Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
• [74] Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3. [PMID: 6021058]
• [75] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [76] Product Information. Apokyn (apomorphine). Mylan Pharmaceuticals Inc, Morgantown, WV.
• [77] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [78] Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
• [79] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [80] Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
• [81] El-Yousef MK, Manier DH "Tricyclic antidepressants and phenothiazines." JAMA 229 (1974): 1419. [PMID: 4152942]
• [82] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [83] Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.